Altimmune(US:ALT) prnewswire.comยท2024-05-21 09:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Altimmune, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its lead product candidate, pemvidutide, during a specified class period [1][2]. Group 1 - The class period for the allegations is from December 1, 2023, to April 26, 2024 [1]. - The complaint claims that Altimmune overstated the potential of pemvidutide compared to competing glucagon-like peptide-1 agonists based on the results from the MOMENTUM Trial [1]. - It is alleged that the results of the MOMENTUM Trial were less significant for pemvidutide's clinical and commercial prospects than what was communicated to investors [1]. Group 2 - The lawsuit also contends that Altimmune's public statements were materially false and misleading, impacting the company's perceived prospects for finding a strategic partner for pemvidutide [1]. - Shareholders are encouraged to register for the class action by July 5, 2024, to participate in potential recovery [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. Group 3 - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].